Alnylam Pharmaceuticals Inc

24 août 2026, 23:11 UTC

Alnylam Pharmaceuticals shares traded lower in after-market hours, retracing from an initial gain. No specific news was identified to explain the movement.

21 août 2026, 23:06 UTC

Alnylam Pharmaceuticals shares are lower in after-market trading, reflecting minor fluctuations since Friday's close without any specific news or developments.

20 août 2026, 23:21 UTC

Alnylam Pharmaceuticals Inc. shares are higher in after-market trading, recovering from earlier lows despite lowered full-year sales guidance for its TTR products.

19 août 2026, 23:06 UTC

Alnylam Pharmaceuticals shares advanced in after-market trading, continuing recent strength following three consecutive higher sessions and trading above its 20-day moving average.

18 août 2026, 23:36 UTC

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

17 août 2026, 23:01 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, despite broader market pressures from geopolitical tensions and rising crude oil prices.

15 août 2026, 00:02 UTC

Alnylam Pharmaceuticals Inc. shares moved higher in after-market trading, despite fluctuating during the session and remaining below the 20-day moving average.

14 août 2026, 22:01 UTC

Alnylam Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified. Broader market concerns stem from a decline in U.S. retail sales.

13 août 2026, 19:36 UTC

Shares of Alnylam Pharmaceuticals are higher today, marking three consecutive daily gains, despite being below the 20-day moving average and a one-month decline.

12 août 2026, 23:16 UTC

Alnylam Pharmaceuticals shares are lower in after-market hours, with no specific news identified. The broader market showed a slight rise in consumer prices.

11 août 2026, 19:46 UTC

Alnylam Pharmaceuticals shares are higher today, buoyed by broader market trends after last Friday's weak jobs report affecting Fed rate hike expectations.

10 août 2026, 22:51 UTC

Alnylam Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip, though still below their 20-day moving average.

7 août 2026, 19:21 UTC

Alnylam Pharmaceuticals is trading higher, supported by a notable rise in the Biotechnology sector. The stock remains below its 20-day moving average.

6 août 2026, 22:52 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, reflecting gains since Thursday's close amid a favorable broader market backdrop.

5 août 2026, 23:01 UTC

Alnylam Pharmaceuticals shares are higher in after-market hours, though no specific news was identified to explain the movement. Recent economic data may be influencing sentiment.

4 août 2026, 23:51 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market optimism over oil supply agreements and easing inflation concerns.

3 août 2026, 20:02 UTC

Raymond James upgraded Alnylam Pharmaceuticals to Strong Buy with a $420 target, contributing to a notable increase in shares during Monday's session.

1 août 2026, 00:01 UTC

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

31 juil. 2026, 23:16 UTC

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

30 juil. 2026, 23:41 UTC

Alnylam Pharmaceuticals is rising in after-market hours, reflecting broader market gains. No specific news was identified to explain the price movement.

29 juil. 2026, 19:14 UTC

Alnylam Pharmaceuticals Inc shares are lower today, influenced by the Federal Reserve's decision to maintain interest rates amid economic uncertainties and sector declines.

28 juil. 2026, 20:02 UTC

Alnylam Pharmaceuticals is trading higher, benefiting from gains in the Biotechnology sector. Recent advancements in its Alzheimer's pipeline are attracting attention.

27 juil. 2026, 22:41 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, continuing a trend of gains over the last three sessions despite remaining below the 20-day moving average.

24 juil. 2026, 19:46 UTC

Alnylam Pharmaceuticals is trading higher, influenced by a rise in the Property & Casualty Insurance sector. Shares remain below their 20-day moving average.

23 juil. 2026, 09:51 UTC

Alnylam Pharmaceuticals shares are modestly higher in pre-market hours, trading within a narrow range since Wednesday's close. The stock remains below its 20-day moving average.

22 juil. 2026, 22:31 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, rebounding from earlier lows despite broader market volatility and geopolitical tensions.

21 juil. 2026, 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

20 juil. 2026, 19:26 UTC

Alnylam Pharmaceuticals is trading higher as it initiates a Phase 2 trial of mivelsiran for Down syndrome-associated Alzheimer’s disease, signaling progress in research.